Literature DB >> 33603030

Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer.

Zhi-Tao Dai1, Li Ma1, Ting-Ting Cao2, Lian Zhu3, Man Zhao1, Ning Li4.   

Abstract

To perform a comparison of the different stereotactic body radiotherapy (SBRT) plans between the Varian EDGE and CyberKnife (CK) systems for locally advanced unresectable pancreatic cancer. Fifteen patients with pancreatic cancer were selected in this study. The median planning target volume (PTV) was 28.688 cm3 (5.736-49.246 cm3). The SBRT plans for the EDGE and CK were generated in the Eclipse and Multiplan systems respectively with the same contouring and dose constrains for PTV and organs at risk (OARs). Dose distributions in PTV were evaluated in terms of coverage, conformity index (CI), new conformity index (nCI), homogeneity index (HI), and gradient index (GI). OARs, including spinal cord, bowel, stomach, duodenum and kidneys were statistically evaluated by different dose-volume metrics and equivalent uniform dose (EUD). The volume covered by the different isodose lines (ISDL) ranging from 10 to 100% for normal tissue were also analyzed. All SBRT plans for EDGE and CK met the dose constraints for PTV and OARs. For the PTV, the dosimetric metrics in EDGE plans were lower than that in CK, except that D99 and GI were slightly higher. The EDGE plans with lower CI, nCI and HI were superior to generate more conformal and homogeneous dose distribution for PTV. For the normal tissue, the CK plans were better at OARs sparing. The radiobiological indices EUD of spinal cord, duodenum, stomach, and kidneys were lower for CK plans, except that liver were higher. The volumes of normal tissue covered by medium ISDLs (with range of 20-70%) were lower for CK plans while that covered by high and low ISDLs were lower for EDGE plans. This study indicated that both EDGE and CK generated equivalent plan quality, and both systems can be considered as beneficial techniques for SBRT of pancreatic cancer. EDGE plans offered more conformal and homogeneous dose distribution for PTV, while the CK plans could minimize the exposure of OARs.

Entities:  

Mesh:

Year:  2021        PMID: 33603030      PMCID: PMC7893157          DOI: 10.1038/s41598-021-83648-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

1.  Stereotactic body radiation therapy: the report of AAPM Task Group 101.

Authors:  Stanley H Benedict; Kamil M Yenice; David Followill; James M Galvin; William Hinson; Brian Kavanagh; Paul Keall; Michael Lovelock; Sanford Meeks; Lech Papiez; Thomas Purdie; Ramaswamy Sadagopan; Michael C Schell; Bill Salter; David J Schlesinger; Almon S Shiu; Timothy Solberg; Danny Y Song; Volker Stieber; Robert Timmerman; Wolfgang A Tomé; Dirk Verellen; Lu Wang; Fang-Fang Yin
Journal:  Med Phys       Date:  2010-08       Impact factor: 4.071

2.  Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848.

Authors:  Ted C Ling; Jerry M Slater; Rachel Mifflin; Prashanth Nookala; Roger Grove; Anh M Ly; Baldev Patyal; Jerry D Slater; Gary Y Yang
Journal:  J Gastrointest Oncol       Date:  2015-04

3.  A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma.

Authors:  Michael W Brown; Holly Ning; Barbara Arora; Paul S Albert; Matthew Poggi; Kevin Camphausen; Deborah Citrin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-01       Impact factor: 7.038

4.  A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD).

Authors:  Gary Luxton; Paul J Keall; Christopher R King
Journal:  Phys Med Biol       Date:  2007-12-13       Impact factor: 3.609

Review 5.  Current status and future perspective of flattening filter free photon beams.

Authors:  Dietmar Georg; Tommy Knöös; Brendan McClean
Journal:  Med Phys       Date:  2011-03       Impact factor: 4.071

6.  The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.

Authors:  Shalini Moningi; Avani S Dholakia; Siva P Raman; Amanda Blackford; John L Cameron; Dung T Le; Ana M C De Jesus-Acosta; Amy Hacker-Prietz; Lauren M Rosati; Ryan K Assadi; Shirl Dipasquale; Timothy M Pawlik; Lei Zheng; Matthew J Weiss; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman
Journal:  Ann Surg Oncol       Date:  2015-01-07       Impact factor: 5.344

Review 7.  Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.

Authors:  Samuel K Kim; Cheng-Chia Wu; David P Horowitz
Journal:  J Gastrointest Oncol       Date:  2016-06

8.  Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis.

Authors:  Rachit Kumar; Aaron T Wild; Mark A Ziegler; Ted K Hooker; Samson D Dah; Phuoc T Tran; Jun Kang; Koren Smith; Jing Zeng; Timothy M Pawlik; Erik Tryggestad; Eric Ford; Joseph M Herman
Journal:  Med Dosim       Date:  2013-03-27       Impact factor: 1.482

9.  Homogeneity Index: An objective tool for assessment of conformal radiation treatments.

Authors:  Tejinder Kataria; Kuldeep Sharma; Vikraman Subramani; K P Karrthick; Shyam S Bisht
Journal:  J Med Phys       Date:  2012-10

10.  Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer.

Authors:  Yoko Goto; Akira Nakamura; Ryo Ashida; Katsuyuki Sakanaka; Satoshi Itasaka; Keiko Shibuya; Shigemi Matsumoto; Masashi Kanai; Hiroyoshi Isoda; Toshihiko Masui; Yuzo Kodama; Kyoichi Takaori; Masahiro Hiraoka; Takashi Mizowaki
Journal:  Radiat Oncol       Date:  2018-06-25       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.